Literature DB >> 12833449

Detection, treatment, and outcome of isolated supraclavicular recurrence in 42 patients with invasive breast carcinoma.

Maurice J C van der Sangen1, Jan-Willem W Coebergh, Rudi M H Roumen, Harm J T Rutten, Gerard Vreugdenhil, Adri C Voogd.   

Abstract

BACKGROUND: There still is debate as to whether breast carcinoma patients with isolated supraclavicular recurrence should be considered to be patients with disseminated disease or patients for whom aggressive treatment with curative intent is justified.
METHODS: In the period 1984-1994, 4669 patients with invasive breast carcinoma underwent axillary dissection in 1 of 8 community hospitals in the southeastern part of the Netherlands. During follow-up, 42 patients with isolated supraclavicular recurrence, without other sites of distant disease, were identified.
RESULTS: The median interval between treatment of the primary tumor and diagnosis of the supraclavicular recurrence was 2.5 years (range, 0.2-11.5 years). Radiotherapy was administered to 25 patients (60%), 5 of whom also underwent surgery and 16 of whom also received chemotherapy or hormonal therapy. Eleven patients received hormonal therapy only, and four received chemotherapy only. One patient received surgical treatment only, and one patient remained untreated. Complete remission was achieved in 35 patients (83%), but a second supraclavicular recurrence occurred in 12 (34% of patients who achieved complete remission). Overall, 6 patients (14%) were alive without evidence of disease after a follow-up period of 4.4-8.3 years. The 5-year actuarial overall survival and distant disease-free survival rates, based on the date of diagnosis of supraclavicular recurrence, were 38% (95% confidence interval [CI], 23-53%) and 22% (95% CI, 8-35%), respectively. The distant disease-free survival rate was somewhat better for the 25 patients who underwent radiotherapy as part of the treatment for supraclavicular recurrence than it was for the 17 patients who did not receive radiotherapy (P = 0.06); the difference became more pronounced after the exclusion of 8 patients who had received axillary and supraclavicular radiotherapy as part of treatment for the primary tumor (P = 0.002).
CONCLUSIONS: Although complete remission can be obtained in most patients with isolated supraclavicular recurrence, the prognosis for these patients is poor. Involved field radiotherapy appears to play an important role in the treatment of supraclavicular recurrence and may improve the distant recurrence-free survival rate. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11469

Entities:  

Mesh:

Year:  2003        PMID: 12833449     DOI: 10.1002/cncr.11469

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Conversion of hormone and HER-2 receptor in metachronous neck metastases from breast carcinoma.

Authors:  Andreas Nauroth; Matthias Kalder; Marion Rössler; Gunnar Wichmann; Andreas Dietz; Susanne Wiegand
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-20       Impact factor: 4.553

2.  Bilateral chylothorax following left supraclavicular lymph node dissection for breast cancer: one case report and literature review.

Authors:  De-Juan Yang; Guo-Sheng Ren; Xiao-Yi Wang
Journal:  Chin J Cancer       Date:  2014-01-02

3.  Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes.

Authors:  Amy J Xu; Carl J DeSelm; Alice Y Ho; Erin F Gillespie; Lior Z Braunstein; Atif J Khan; Beryl McCormick; Simon N Powell; Oren Cahlon
Journal:  Adv Radiat Oncol       Date:  2019-03-01

4.  Long-Term Outcomes of Breast Cancer Patients Who Underwent Selective Neck Dissection for Metachronous Isolated Supraclavicular Nodal Metastasis.

Authors:  Shin-Cheh Chen; Shih-Che Shen; Chi-Chang Yu; Ting-Shuo Huang; Yung-Feng Lo; Hsien-Kun Chang; Yung-Chang Lin; Wen-Ling Kuo; Hsiu-Pei Tsai; Hsu-Huan Chou; Li-Yu Lee; Yi-Ting Huang
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

5.  DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences.

Authors:  Wolfgang Harms; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; D Krug; M D Piroth; M-L Sautter-Bihl; F Sedlmayer; R Souchon; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2016-03-01       Impact factor: 3.621

6.  Cervical Lymph Node Involvement above the Supraclavicular Fossa in Breast Cancer: Comparison with Stage IIIC (KROG 18-02).

Authors:  Jae Sik Kim; Kyubo Kim; Kyung Hwan Shin; Jin Ho Kim; Seung Do Ahn; Su Ssan Kim; Yong Bae Kim; Jee Suk Chang; Doo Ho Choi; Won Park; Tae Hyun Kim; Mison Chun; Jihye Cha; Jin Hee Kim; Dong Soo Lee; Sun Young Lee; Hae Jin Park
Journal:  J Breast Cancer       Date:  2020-02-13       Impact factor: 3.588

7.  Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis.

Authors:  Hitoshi Inari; Natsuki Teruya; Miki Kishi; Rie Horii; Futoshi Akiyama; Shunji Takahashi; Yoshinori Ito; Takayuki Ueno; Takuji Iwase; Shinji Ohno
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

Review 8.  Loco-regional therapy for isolated locoregional lymph node recurrence of breast cancer: focusing on surgical treatment with combined therapy.

Authors:  Kaori Terata; Ayuko Yamaguchi; Ayano Ibonai; Kazuhiro Imai; Akiyuki Wakita; Yusuke Sato; Satoru Motoyama; Yoshihiro Minamiya
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.